Nutrichem(BJ:833819)2023-04-25 16:00Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 70,545,123.01, a significant decrease of 72.89% compared to CNY 260,178,554.04 in the same period last year[9]. - Operating revenue for Q1 2023 was CNY 1,642,558,394.27, down 27.10% from CNY 2,253,210,484.92 year-on-year[9]. - The company reported a net loss of ¥33,207,066.22 for the first quarter of 2023, compared to a net profit of ¥289,666,777.48 in the same period of 2022, indicating a significant decline in profitability[87]. - Total operating revenue for Q1 2023 was ¥1,642,558,394.27, a decrease of 27.1% compared to ¥2,253,210,484.92 in Q1 2022[82]. - The company reported a total comprehensive income of ¥66,822,969.80 for Q1 2023, down from ¥267,299,941.53 in Q1 2022[84]. - The company's basic earnings per share (EPS) for Q1 2023 was -¥0.03, compared to ¥0.24 in Q1 2022, indicating a substantial drop in earnings per share[87]. Cash Flow and Assets - The net cash flow from operating activities decreased by 209.25%, resulting in a negative cash flow of CNY -187,566,831.47[11]. - Operating cash flow for the first quarter of 2023 was negative at ¥187,566,831.47, a stark contrast to a positive cash flow of ¥171,683,272.34 in the first quarter of 2022[91]. - The company’s cash and cash equivalents at the end of Q1 2023 stood at ¥1,019,782,862.67, down from ¥1,190,400,519.24 at the beginning of the quarter, resulting in a net decrease of ¥170,617,656.57[92]. - The company incurred total cash outflows from financing activities of ¥676,236,897.88 in Q1 2023, down from ¥961,371,205.40 in Q1 2022, reflecting a decrease of about 29.6%[92]. - The company’s total cash outflow from operating activities was ¥1,695,380,859.24 in Q1 2023, compared to ¥2,113,498,393.80 in Q1 2022, representing a decrease of about 19.7%[91]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,876[15]. - The largest shareholder, Huabang Life Health Co., Ltd., holds 45.82% of the shares, totaling 561,683,154 shares[17]. - The total shares held by major shareholders amounted to 872,984,281, representing 71.16% of the total shares[19]. - The company has a strict cash dividend policy in place, aiming to provide stable returns to investors over the next three years[40]. - The company has committed to a profit distribution policy that ensures at least 10% of the annual distributable profit is distributed in cash, with a cumulative cash distribution of no less than 30% of the average annual distributable profit over the last three years[65]. Operational Strategy - The company plans to adjust its operational strategies to maintain market share and ensure order fulfillment in response to increased competition and declining market demand[11]. - The company will improve internal controls to enhance fund management and prevent misappropriation of funds, thereby increasing profit margins[41]. - The company has outlined measures to enhance profitability and protect the rights of minority investors[38]. Compliance and Commitments - The company has timely fulfilled its obligations regarding external guarantees and related party transactions[24]. - The company commits to using raised funds effectively and will establish a special account for fund management to ensure compliance with regulations[38]. - The company will adhere to legal regulations regarding stock reduction and ensure timely and accurate information disclosure[35]. - The company ensures that all commitments made by its controlling shareholder and actual controller regarding the public offering are legally binding and will not be waived due to changes in their positions[45]. Asset Management - Total assets as of March 31, 2023, amounted to CNY 12,616,797,387.50, representing a 0.56% increase from the end of the previous year[9]. - The company's asset-liability ratio (consolidated) improved slightly to 52.44% from 52.72% at the end of the previous year[9]. - The total amount of restricted assets is approximately 2.39 billion yuan, accounting for 18.90% of total assets, primarily used for securing loans[70]. Research and Development - Research and development expenses for Q1 2023 were ¥49,743,368.63, a slight increase from ¥49,149,941.80 in Q1 2022[82].